Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
With
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant must have documented diagnosis of untreated de novo MDS with:
* International Prognostic Scoring System (IPSS) risk categories Int-2 or High (minimum IPSS overall score of 1.5) OR Revised IPSS (IPSS-R) categories intermediate, high or very high (score of \> 3) and
* Presence of less than 20% bone marrow blasts per bone marrow biopsy/aspirate.
Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.
You may not be if
Participant has received prior therapy for MDS. (Prior supportive care in form of transfusions or growth factors, etc., is not considered prior therapy).
Participant has received prior therapy with a BCL-2 Homology 3 (BH3) mimetic.
Participant has a diagnosis other than previously untreated de novo MDS (as defined in the protocol) including:
* MDS with IPSS risk categories Low or Int-1 (overall IPSS score \< 1.5)
* Therapy-related MDS (t-MDS).
* MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).
* MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.
Participant has received allogeneic Hematopoietic Stem Cell Transplantation (HSCT) or solid organ transplantation.
Participant has received a live attenuated vaccine within 4 weeks prior to the first dose of study drug.
Clareo Health | A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
